Dogwood Therapeutics Inc (DWTX) Stock Price, Quote & News

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a co...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 620 8655

Website: dwtx.com

Address:

44 Milton Avenue, Alpharetta, United States

jrothman22 Jul. 24 at 6:50 PM

$DWTX Will my CVR shares ever be worth anything?

2 · Reply

Drainomight Jul. 24 at 1:51 PM

$DWTX wound up tight

0 · Reply

cfvk Jul. 23 at 10:50 PM

$DWTX seems to be basing 1.3/1.4s? maybe

0 · Reply

Drainomight Jul. 22 at 8:54 PM

$DWTX

0 · Reply

TrustFundBaby Jul. 22 at 7:58 PM

$DGNX $MSS $DWTX ➡️➡️➡️ WKSP Going parabolic!! 🚀🚀🚀 SUPER CHEAP!! 👇👇👇👇 ----WKSP----

0 · Reply

DylanGFM Jul. 22 at 7:32 PM

$DGNX $MSS $DWTX THESE TICKERS DON'T JUST COME AROUN FOR NO REASON! well, sometimes they do 😂 BUT STILL! ON WATCH

0 · Reply

hammerfall43 Jul. 22 at 4:11 PM

$DWTX give me 1$

0 · Reply

ByBi Jul. 22 at 11:50 AM

$DWTX BOTTOM ALERT 👍

1 · Reply

SquirrelLord Jul. 17 at 8:05 PM

$DWTX dogwood therapeutics to the mooooonnnn 🌝

0 · Reply

fda_tracker Jul. 13 at 7:37 PM

$DWTX Phase 2 trial w/est Jul completion date NCT06848348: https://www.clinicaltrials.gov/study/NCT06848348 Trial Tracker: https://www.fdatracker.com/trial-tracker/

0 · Reply

Dogwood enrolls first 200 patients in HAL-CINP trial

Jul 20, 2026, 8:30 AM EDT - 4 days ago

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Jun 30, 2026, 8:45 AM EDT - 24 days ago

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

Jun 30, 2026, 7:00 AM EDT - 24 days ago

Dogwood Therapeutics Slides: Corporate presentation

2026-05-18T13:19:18.000Z - 2 months ago

Dogwood begins Phase 2b extension study for Halneuron

May 18, 2026, 8:45 AM EDT - 2 months ago

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

May 14, 2026, 9:30 AM EDT - 2 months ago

Dogwood Therapeutics Earnings release: Q1 2026

May 14, 2026, 9:30 AM EDT - 2 months ago

Dogwood Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

May 12, 2026, 2:00 AM EDT - 2 months ago

Dogwood Therapeutics Slides: Corporate presentation

May 7, 2026, 8:30 AM EDT - 2 months ago

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Dogwood Therapeutics Proxy statement: Proxy filing

2026-04-23T13:30:03.000Z - 3 months ago

Dogwood announces commercialization partnership with PRIDCor

Apr 23, 2026, 9:00 AM EDT - 3 months ago

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Dogwood Therapeutics Proxy statement: Proxy filing

2026-04-15T13:22:56.000Z - 3 months ago

Dogwood announces FDA acceptance of SP16 investigational new drug application

Apr 15, 2026, 9:00 AM EDT - 3 months ago

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Mar 18, 2026, 9:00 AM EDT - 4 months ago

Dogwood Therapeutics Annual report: Q4 2025

Mar 18, 2026, 9:00 AM EDT - 4 months ago

Dogwood Therapeutics Earnings release: Q4 2025

2026-03-18T12:42:15.000Z - 4 months ago

Dogwood sees cash runway into 4Q26

Mar 18, 2026, 8:30 AM EDT - 4 months ago

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 13, 2026, 7:00 AM EST - 5 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

2026-02-02T13:35:35.000Z - 6 months ago

Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial

Feb 2, 2026, 8:30 AM EST - 6 months ago

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

Jan 26, 2026, 6:00 AM EST - 6 months ago

Dogwood Therapeutics Slides: Investor presentation

Jan 23, 2026, 7:00 AM EST - 6 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

2026-01-15T21:25:14.000Z - 6 months ago

Dogwood files to sell 6.43M shares of common stock for holders

Jan 15, 2026, 7:00 AM EST - 6 months ago

Dogwood Therapeutics Registration statement: Registration Filing

2026-01-12T13:55:35.000Z - 6 months ago

Dogwood announces financing of up to $26.8M

Jan 12, 2026, 8:30 AM EST - 6 months ago

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

2025-12-22T15:20:25.000Z - 7 months ago

Dogwood announces interim Phase 2b trial results on Halneuron

Dec 22, 2025, 10:15 AM EST - 7 months ago

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

2025-12-02T13:30:43.000Z - 8 months ago

Dogwood files for IP protection for synthetic Halneuron

Dec 2, 2025, 8:00 AM EST - 8 months ago

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

Nov 21, 2025, 10:00 AM EST - 8 months ago

Dogwood Therapeutics Transcript: EGM 2025

2025-11-11T13:55:32.000Z - 9 months ago

Dogwood enrolls first 100 patients in Halneuron Phase 2b trial

Nov 11, 2025, 8:45 AM EST - 9 months ago

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Nov 6, 2025, 8:45 AM EST - 9 months ago

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 9 months ago

Dogwood Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Dogwood Therapeutics Earnings release: Q3 2025

Oct 30, 2025, 9:15 AM EDT - 9 months ago

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Dogwood Therapeutics Registration statement: Registration Filing

Oct 14, 2025, 8:45 AM EDT - 10 months ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Oct 9, 2025, 8:00 AM EDT - 10 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 10 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

2025-10-07T13:30:11.000Z - 10 months ago

Dogwood to present on Halneuron pain research program

Oct 7, 2025, 8:45 AM EDT - 10 months ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

2025-10-01T20:20:32.000Z - 10 months ago

Dogwood files to sell 28.04M shares of common stock for holders

Oct 1, 2025, 8:00 AM EDT - 10 months ago

Dogwood Therapeutics Registration statement: Registration Filing

2025-09-30T10:15:45.000Z - 10 months ago

Dogwood price target raised to $12 from $10 at H.C. Wainwright

Sep 29, 2025, 8:30 AM EDT - 10 months ago

Dogwood Therapeutics Transcript: Study Update

Sep 29, 2025, 8:30 AM EDT - 10 months ago

Dogwood Therapeutics Press release: Study Update

Sep 29, 2025, 8:30 AM EDT - 10 months ago

Dogwood Therapeutics Slides: Study Update

Sep 29, 2025, 8:00 AM EDT - 10 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

2025-09-29T11:20:42.000Z - 10 months ago

Dogwood secures royalty free license to develop, commercialize SP16

Sep 29, 2025, 7:15 AM EDT - 10 months ago

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Sep 5, 2025, 7:00 AM EDT - 11 months ago

Dogwood Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 11 months ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 9:30 AM EDT - 1 year ago

Dogwood Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 1 year ago

Dogwood Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 6:00 PM EDT - 1 year ago

Dogwood Therapeutics Slides: Corporate Presentation

Aug 7, 2025, 1:08 PM EDT - 1 year ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 6, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Jun 11, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: Sidoti's Small-Cap Virtual Conference

Jun 3, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

May 23, 2025, 8:00 AM EDT - 1 year ago

Dogwood Therapeutics Registration statement: Registration Filing

May 8, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 8, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Quarterly report: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Earnings release: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 3, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Mar 31, 2025, 3:45 PM EDT - 1 year ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 31, 2025, 1:30 PM EDT - 1 year ago

Dogwood Therapeutics Annual report: Q4 2024

Mar 31, 2025, 1:30 PM EDT - 1 year ago

Dogwood Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 8:45 AM EDT - 1 year ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 13, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Nov 7, 2024, 8:30 AM EST - 1 year ago

Dogwood Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Dogwood Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Dogwood Therapeutics Earnings release: Q3 2024

Oct 17, 2024, 9:30 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: M&A Announcement

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics Press release: M&A Announcement

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics Slides: M&A Announcement

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Aug 8, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Dogwood Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Dogwood Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 9:41 AM EDT - 2 years ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 23, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

May 22, 2024, 1:30 PM EDT - 2 years ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 2 years ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 2 years ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 9, 2024, 8:30 AM EDT - 2 years ago

Dogwood Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Dogwood Therapeutics Quarterly report: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Dogwood Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:45 AM EDT - 2 years ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Mar 26, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Feb 29, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 8:00 AM EST - 2 years ago

Dogwood Therapeutics Annual report: Q4 2023

Feb 29, 2024, 8:00 AM EST - 2 years ago

Dogwood Therapeutics Earnings release: Q4 2023

Feb 28, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Feb 27, 2024, 7:00 AM EST - 2 years ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Feb 2, 2024, 7:00 AM EST - 2 years ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Jan 22, 2024, 9:00 AM EST - 2 years ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 22, 2024, 7:00 AM EST - 2 years ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Jan 2, 2024, 7:05 AM EST - 2 years ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Nov 13, 2023, 8:30 AM EST - 2 years ago

Dogwood Therapeutics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Dogwood Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Dogwood Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Oct 12, 2023, 7:05 AM EDT - 3 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Sep 18, 2023, 7:05 AM EDT - 3 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 12, 2023, 7:05 AM EDT - 3 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

jrothman22 Jul. 24 at 6:50 PM

$DWTX Will my CVR shares ever be worth anything?

2 · Reply

Drainomight Jul. 24 at 1:51 PM

$DWTX wound up tight

0 · Reply

cfvk Jul. 23 at 10:50 PM

$DWTX seems to be basing 1.3/1.4s? maybe

0 · Reply

Drainomight Jul. 22 at 8:54 PM

$DWTX

0 · Reply

TrustFundBaby Jul. 22 at 7:58 PM

$DGNX $MSS $DWTX ➡️➡️➡️ WKSP Going parabolic!! 🚀🚀🚀 SUPER CHEAP!! 👇👇👇👇 ----WKSP----

0 · Reply

DylanGFM Jul. 22 at 7:32 PM

$DGNX $MSS $DWTX THESE TICKERS DON'T JUST COME AROUN FOR NO REASON! well, sometimes they do 😂 BUT STILL! ON WATCH

0 · Reply

hammerfall43 Jul. 22 at 4:11 PM

$DWTX give me 1$

0 · Reply

ByBi Jul. 22 at 11:50 AM

$DWTX BOTTOM ALERT 👍

1 · Reply

SquirrelLord Jul. 17 at 8:05 PM

$DWTX dogwood therapeutics to the mooooonnnn 🌝

0 · Reply

fda_tracker Jul. 13 at 7:37 PM

$DWTX Phase 2 trial w/est Jul completion date NCT06848348: https://www.clinicaltrials.gov/study/NCT06848348 Trial Tracker: https://www.fdatracker.com/trial-tracker/

0 · Reply

BillionerOfKing Jul. 9 at 9:50 PM

$DWTX Current Stock Price: $1.39

0 · Reply

Drainomight Jul. 7 at 1:57 PM

$DWTX shake them out

0 · Reply

Guillaume_Fr Jul. 7 at 11:53 AM

$DWTX Just made a solid entry position here. I’m looking forward to what the end of 2026 will bring, and I see Ian Dukes joining the company as a very positive move.

0 · Reply

hammerfall43 Jul. 2 at 9:11 PM

$DWTX 1 $ coming soon

0 · Reply

BioTuesdays Jun. 30 at 7:18 PM

$DWTX has announced the appointment of Iain Dukes, PhD, as chair of the company’s scientific advisory board (SAB). https://biotuesdays.com/2026/06/30/dr-iain-dukes-joins-dogwood-as-chair-of-sab/

0 · Reply

investimakerrr Jun. 26 at 6:48 PM

$DWTX 400 shares here ... i know armi didnt sell them share yet.... and now the chart isnow signaling...oh yeah...almost game time!

1 · Reply

tboykeyhoang Jun. 25 at 3:11 PM

$DWTX no trading ?

0 · Reply

missfendi Jun. 24 at 6:48 AM

$DWTX this isn’t recovering as it’s

0 · Reply

beam_____ Jun. 17 at 10:42 PM

$DWTX Slow slow slow…

1 · Reply

vcaelum Jun. 17 at 10:12 PM

$DWTX So the board approved the increase of authorized shares from 43 million to 195m shares. And the preferred stock from 2 million to 5 million shares? Based on the latest 8k

0 · Reply

SuperGreenToday Jun. 16 at 1:45 AM

$DWTX

0 · Reply

ByBi Jun. 12 at 9:27 AM

$DWTX 85 % of the float is locked up share price trading right below its 20 & 50 dma for extended time. should they come up with positive outcome on their halneuron trials (wich i think they will....) this could sky rocket as fock. watching..... 👀👇

1 · Reply

Market Cap	49.10M
Revenue (ttm)	0.00
Net Income (ttm)	-34.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	18,800
Avg Vol	83,810
Day's Range	N/A - N/A
Shares Out	33.63M
Stochastic %K	56%
Beta	1.70
Analysts	Strong Sell
Price Target	$14.00